A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This study will be a pilot study of sorafenib 400mg PO twice daily in refractory T-cell
lymphomas including peripheral T-cell lymphoma (PTCL), angioimmunoblastic lymphadenopathy
(AILD), cutaneous T cell lymphoma (CTCL), anaplastic large cell lymphoma (ALCL) and other
transformed T-cell lymphomas with the primary objective of studying the biological effects of
the multikinase inhibitor, sorafenib.